ClinicalTrials.gg
CompletedNCT03655054Updated Oct 17, 2022Results posted

eCoin for OAB Feasibility Follow-on Study

An interventional study of eCoin Tibial Nerve Stimulation in Overactive Bladder, Urge Incontinence and Incontinence, Urinary, sponsored by Valencia Technologies Corporation. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-17.

Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.

Enrollment
213th of 288
23 · median 66
Started
2019
with 18 others
No phase
113 of 333
20 open now
Registered
205th of 333
by date

Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 213th largest by enrollment of the 288 interventional ones that give a count, is one of 19 that started in 2019, is one of 113 with no phase, and was the 205th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Urinary Bladder, Overactive with a site in United States, or all of them as a file.
02

Study summary

This trial is a prospective, multicenter, single-arm follow-on study will evaluate the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects with urgency urinary incontinence (UUI) as defined by the American Urological Association (30). The follow-on study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient-reported outcomes through 24 weeks of eCoinTM therapy (which is the same as 28 weeks from study device reimplantation).

03

Conditions studied

  • Overactive Bladder
  • Urge Incontinence
  • Incontinence, Urinary
  • Urinary Urge Incontinence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individual participated in the eCoin Feasibility Study for Urgency Urinary Incontinence.
  2. Individual was implanted with the study device during the eCoin Feasibility Study for Urgency Urinary Incontinence.

Exclusion criteria

Exclusion Criteria:

  1. In the opinion of the investigator, individual is not a good candidate for participation in the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    eCoin Tibial Nerve Stimulation

    Device: eCoin Tibial Nerve Stimulation

Interventions

  • DeviceeCoin Tibial Nerve Stimulation

    Subcutaneous stimulation of the tibial nerve using the eCoin device.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

    Time frame: 12 weeks after device activation.

  2. Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 4 Months After Implantation.

    Instances of a related adverse event.

    Time frame: 16 weeks after device implantation.

Secondary outcomes

  1. Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

    Time frame: 24 weeks after device activation.

  2. Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 6 Months After Implantation.

    Instances of a related adverse event

    Time frame: 28 weeks after device implantation.

07

Results

Posted Apr 26, 2021

Participant flow

Participant flow — Overall Study
MilestoneeCoin Tibial Nerve Stimulation
Started23
Completed22
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Time frame:
12 weeks after device activation.
Reported as:
Mean · episodes/day
Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
episodes/dayeCoin Tibial Nerve Stimulation
Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.-2.2 ± 3.3
PrimarySafety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 4 Months After Implantation.

Instances of a related adverse event.

Time frame:
16 weeks after device implantation.
Reported as:
Number · adverse events
Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 4 Months After Implantation.
adverse eventseCoin Tibial Nerve Stimulation
Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 4 Months After Implantation.8
SecondaryChange From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Time frame:
24 weeks after device activation.
Reported as:
Mean · episodes/day
Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
episodes/dayeCoin Tibial Nerve Stimulation
Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.-3.7 ± 1.2
SecondarySafety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 6 Months After Implantation.

Instances of a related adverse event

Time frame:
28 weeks after device implantation.
Reported as:
Number · adverse events
Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 6 Months After Implantation.
adverse eventseCoin Tibial Nerve Stimulation
Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 6 Months After Implantation.8

Adverse events

Collected over 28 weeks after implantation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
eCoin Tibial Nerve Stimulation0/23 (0%)0/23 (0%)6/23 (26.1%)
Most frequent other events
Most frequent other events
EventeCoin Tibial Nerve Stimulation
Incision site discomfortGeneral disorders3/23
Incision site swellingGeneral disorders3/23
Incision site erythemaSkin and subcutaneous tissue disorders1/23
DermatitisSkin and subcutaneous tissue disorders1/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)eCoin Tibial Nerve Stimulation
<=18 years0
Between 18 and 65 years9
>=65 years14
Age, Continuous
Age, Continuous(years)eCoin Tibial Nerve Stimulation
Mean63.6 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)eCoin Tibial Nerve Stimulation
Female22
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)eCoin Tibial Nerve Stimulation
Hispanic or Latino0
Not Hispanic or Latino23
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)eCoin Tibial Nerve Stimulation
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White23
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)eCoin Tibial Nerve Stimulation
New Zealand9
United States14
Mean UUI Episodes/Day
Mean UUI Episodes/Day(episodes/day)eCoin Tibial Nerve Stimulation
Mean4.8 ± 3.2
08

Study locations

7 sites
  • The Clark Center for Urogynecology
    Newport Beach, California 92663, United States
  • UnityPoint Clinic
    Waterloo, Iowa 50703, United States
  • Alliance Urology Specialists
    Greensboro, North Carolina 27403, United States
  • The Institute for Female Pelvic Medicine & Reconstructive Surgery (FPM Institute)
    Allentown, Pennsylvania 18103, United States
  • Urology Associates
    Christchurch, 8013, New Zealand
  • Roundhay Medical Centre
    Nelson, New Zealand
  • Tauranga Urology Research Ltd
    Tauranga, New Zealand
09

References and documents

Publications

  • Kaaki B, English S, Gilling P, Meffan P, Lucente V, MacDiarmid S, Clark M, Sen SK. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022 May 1;28(5):287-292. doi: 10.1097/SPV.0000000000001105. Epub 2022 Sep 22. PubMed 35536667 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jan 2020, 10 months.

Results were first posted in Apr 2021, 1 year 2 months after primary completion.

Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 10 months is below that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2018
First posted
Aug 31, 2018
StartActual
Mar 13, 2019
Primary completionActual
Jan 31, 2020
CompletionActual
Sep 12, 2022
Results first posted
Apr 26, 2021
Last update
Oct 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03655054
Lead sponsor
Valencia Technologies Corporation
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Mar 13, 2019
Primary completion
Jan 31, 2020
Completion
Sep 12, 2022
Results posted
Apr 26, 2021
Last update
Oct 17, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion